Core and Main Inc vs Stryker Corporation — how do they compare? Core and Main Inc trades at $46.18 (market cap $8.73B), while Stryker Corporation trades at $346.82 (market cap $133.54B). The key difference: Stryker Corporation is far larger — about 15.3× Core and Main Inc's market cap, and Stryker Corporation pays a 1.01% dividend while Core and Main Inc pays none. Which is the better fit depends on your goals.
| CNM | SYK | |
|---|---|---|
Market Cap | $8.73B | $133.54B |
Sector | Technology | Technology |
52-Week High | $66.98 | $394.34 |
52-Week Low | $42.37 | $282.58 |
Enterprise Value | $11.02B | $145.01B |
Dividend Yield | — | 1.01% |
Signals from Pluang's Aura AI — not financial advice
Core & Main (CNM) trades at $46.06, down 0.52% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.57 exceeding expectations. Financials show solid profitability with a 5.87% net income margin and 23.73% ROE, though debt levels remain elevated. Recent news includes institutional position adjustments and a $750 million senior notes offering priced in June 2026.
Outlook is cautiously optimistic with analyst consensus favoring Buy ratings (57%). Key opportunities include margin expansion and municipal strength, while risks involve high debt, competitive pressures, and reliance on infrastructure spending. The stock's valuation at a P/E of 19.76 appears reasonable given growth prospects, but investors should monitor execution against FY26 revenue guidance of $7.8–7.9 billion.
Stryker (SYK) trades at $347.21, up 0.4% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, including a 9% organic sales growth in Q2 2026 and a net income margin of 14.43%. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS, expanding its robotic surgery portfolio. Analyst consensus is overwhelmingly positive, with 74% recommending Buy and a price target of $379.44.
The outlook for SYK is favorable, driven by robust earnings growth and strategic product launches. Key risks include cybersecurity vulnerabilities and margin pressures from tariffs. With no sell ratings and strong institutional support, the stock presents a compelling opportunity for growth-oriented investors, though monitoring quarterly execution remains critical.
Trailing returns across standard periods
Latest headlines on both assets
Core & Main is a leading US distributor of water, wastewater, storm drainage, and fire protection products. It provides essential infrastructure solutions to municipalities, private water companies, and contractors.
Read more on CNM →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →